呼吸系統相關的聯盟契約動向 (2014∼2020):交易的趨勢，企業，財務分析

本報告提供呼吸疾病相關的事業聯盟相關契約分析，聯盟契約的整體締結趨勢，及各業界、各症狀等詳細趨勢，交易的條件 (交易額、付款條件等)，主要企業的簡介與契約締結趨勢，其他資本交易、事業聯盟的締結趨勢等資訊彙整，為您概述為以下內容。

摘要整理

第1章 簡介

第2章 呼吸系統相關的交易締結趨勢

• 簡介
• 多年的呼吸系統相關合作關係
• 呼吸系統相關的聯盟趨勢:各交易類型
• 呼吸系統相關的聯盟趨勢:各業界
• 呼吸系統相關的聯盟趨勢:各開發階段
• 呼吸系統相關的聯盟趨勢:各技術種類
• 呼吸系統相關的聯盟趨勢:各適應症

第3章 呼吸系統相關的聯盟相關金融交易條件

• 簡介
• 呼吸系統相關的聯盟:明確指示的財務條件
• 呼吸系統相關的聯盟:契約總額
• 呼吸系統相關的資本交易:預付款金
• 呼吸系統相關的資本交易:里程碑 (每次到達目標) 支付金
• 呼吸系統相關的聯盟:權利金比率 (使用費用率)

第4章 呼吸系統相關的主要交易內容與交易締結者

• 簡介
• 呼吸系統相關的聯盟:最活躍的合作夥伴
• 呼吸系統相關的聯盟:最活躍的合作公司的一覽
• 最高契約金額 (各金額)

第5章 呼吸系統相關的契約文件名錄

• 簡介
• 契約文件公開的聯盟契約

第6章 呼吸系統相關的契約動向:各治療標的

• 簡介
• 契約動向:各呼吸疾病治療標的

附錄

The Global Respiratory Partnering 2010-2022: Deal trends, players and financials report provides comprehensive understanding and unprecedented access to the respiratory partnering deals and agreements entered into by the worlds leading healthcare companies

Global Respiratory Partnering 2010 to 2022 provides the full collection of Respiratory disease deals signed between the world's pharmaceutical and biotechnology companies since 2010.

Trends in Respiratory partnering deals

Financial deal terms for headline, upfront and royalty by stage of development

Respiratory partnering agreement structure

Respiratory partnering contract documents

Top Respiratory deals by value

Most active Respiratory dealmakers

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive Respiratory disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Respiratory deals.

The report presents financial deal terms values for Respiratory deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

The initial chapters of this report provide an orientation of Respiratory dealmaking trends.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in Respiratory dealmaking since 2010 covering trends by year, deal type, stage of development, technology type and therapeutic indication.

Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.

Chapter 4 provides a review of the leading Respiratory deals since 2010. Deals are listed by headline value. The chapter includes the top 25 most active Respiratory dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 5 provides comprehensive access to Respiratory deals since 2010 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of all Respiratory partnering deals by specific Respiratory target announced since 2010. The chapter is organized by specific Respiratory therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided with each report of all Respiratory partnering deals signed and announced since 2010. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Respiratory partnering and dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Respiratory technologies and products.

Report scope

Global Respiratory Partnering 2010 to 2022 is intended to provide the reader with an in-depth understanding and access to Respiratory trends and structure of deals entered into by leading companies worldwide.

Global Respiratory Partnering 2010 to 2022 includes:

• Trends in Respiratory dealmaking in the biopharma industry since 2010
• Access to headline, upfront, milestone and royalty data
• Access to hundreds of Respiratory deal contract documents
• Comprehensive access to over 1000 Respiratory deal records
• The leading Respiratory deals by value since 2010
• Most active Respiratory dealmakers since 2010
• The report includes deals for the following indications: Allergic rhinitis, Acute respiratory distress syndrome, Asthma, Bronchitis, Chronic obstructive pulmonary disease, Emphysema, Idiopathic pulmonary fibrosis, Occupational Lung Disease, Asbestosis, Coalworkers pneumoconiosis, Hypersensitivity pneumonitis, Silicosis, Pneumonia, Pulmonary arterial hypertension, Pulmonary embolism, Respiratory Tract Infection, Sarcoidosis, Sinusitis, Breathlessness, Bronchospasm, Chest Pain, Cough, Nasal congestation, Snoring, Wheeze, plus other respiratory indications.

In Global Respiratory Partnering 2010 to 2022, available deals and contracts are listed by:

• Headline value
• Upfront payment value
• Royalty rate value
• Stage of development at signing
• Deal component type
• Technology type
• Specific therapy indication
• Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Global Respiratory Partnering 2010 to 2022 report provides comprehensive access to available deals and contract documents for over 1000 respiratory deals. Analyzing actual contract agreements allows assessment of the following:

• What are the precise rights granted or optioned?
• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are the sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Benefits

Global Respiratory Partnering 2010 to 2022 provides the reader with the following key benefits:

• In-depth understanding of Respiratory deal trends since 2010
• Access Respiratory deal headline, upfront, milestone and royalty data
• Research hundreds of actual contracts between Respiratory partner companies
• Comprehensive access to over 1000 links to actual Respiratory deals entered into by the world's biopharma companies
• Indepth review of Respiratory deals entered into by the top 25 most active dealmakers
• Benchmark the key deal terms companies have agreed in previous deals
• Identify key terms under which companies partner Respiratory opportunities
• Uncover companies actively partnering Respiratory opportunities

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Respiratory dealmaking

• 2.1. Introduction
• 2.2. Respiratory partnering over the years
• 2.3. Respiratory partnering by deal type
• 2.4. Respiratory partnering by industry sector
• 2.5. Respiratory partnering by stage of development
• 2.6. Respiratory partnering by technology type
• 2.7. Respiratory partnering by therapeutic indication

Chapter 3 -Financial deal terms for Respiratory partnering

• 3.1. Introduction
• 3.2. Disclosed financials terms for Respiratory partnering
• 3.3. Respiratory partnering headline values
• 3.4. Respiratory deal upfront payments
• 3.5. Respiratory deal milestone payments
• 3.6. Respiratory royalty rates

Chapter 4 - Leading Respiratory deals and dealmakers

• 4.1. Introduction
• 4.2. Most active in Respiratory partnering
• 4.3. List of most active dealmakers in Respiratory
• 4.4. Top Respiratory deals by value

Chapter 5 - Respiratory contract document directory

• 5.1. Introduction
• 5.2. Respiratory partnering deals where contract document available

Chapter 6 - Respiratory dealmaking by therapeutic target

• 6.1. Introduction
• 6.2. Deals by Respiratory therapeutic target

Appendices

• Appendix 1 - Directory of Respiratory deals by company A-Z 2010 to 2022
• Appendix 2 - Directory of Respiratory deals by deal type 2010 to 2022
• Appendix 3 - Directory of Respiratory deals by stage of development 2010 to 2022
• Appendix 4 - Directory of Respiratory deals by technology type 2010 to 2022
• Further reading on dealmaking
• Deal type definitions

About Wildwood Ventures

• Current Partnering
• Current Agreements
• Recent report titles from CurrentPartnering

Table of figures

• Figure 1: Respiratory partnering since 2010
• Figure 2: Respiratory partnering by deal type since 2010
• Figure 3: Respiratory partnering by industry sector since 2010
• Figure 4: Respiratory partnering by stage of development since 2010
• Figure 5: Respiratory partnering by technology type since 2010
• Figure 6: Respiratory partnering by indication since 2010
• Figure 7: Respiratory deals with a headline value
• Figure 8: Respiratory deals with upfront payment values
• Figure 9: Respiratory deals with milestone payment
• Figure 10: Respiratory deals with royalty rates
• Figure 11: Active Respiratory dealmaking activity- 2010 to 2022
• Figure 12: Top Respiratory deals by value since 2010